



Mercedes Meyer Presents at ACI's Biosimilars and Innovator Biologics Summit

Shareholder Mercedes Meyer, Ph.D. gave two presentations at the American Conference Institute's (ACI) summit on Biosimilars and Innovator Biologics on June 2 and 3 in Boston.

The first presentation, "Innovator Strategies in a Biosimilar Era: Managing Competition, Driving Innovation, and Maintaining Market Position," explored the legal, regulatory, and commercial challenges that the innovator biologics community faces. Additional topics included:

- Developing next-generation biologics with improved efficacy or new indications
- Actively managing IP to extend exclusivity
- Engaging in robust clinical trials to solidify the safety and efficacy profile of the original drug
- Exploring new therapeutic areas with high unmet medical needs

Mercedes' second presentation, "Ethical Considerations in Biologics & Biosimilars: Addressing Fairness, Access, and Innovation," discussed the ethical responsibilities of those in the biologics and biosimilars industry. The session also touched on:

- Balancing fair market competition in BPCIA litigation while ensuring patient access to affordable treatments
- Addressing the role of pricing strategies, formulary decisions, and exclusivity periods in shaping healthcare equity
- Mitigating the risks of biased data sets in clinical research and ensuring diverse patient representation
- Upholding ethical standards in patent litigation, including challenges to evergreening and anti-competitive practices
- Examining professional responsibility and ethics in legal practice, including access to PTAB representation and emerging regulatory considerations

You can read more about this event by [clicking here](#).